Kasugamycin Inhibits Chit1 to Treat Fibrosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic approaches for fibrotic diseases, such as pulmonary fibrosis, are inadequate in directly addressing the mechanisms of fibrosis, particularly the role of Chitinase 1 (Chit1) and Transforming Growth Factor Beta 1 (TGFβ1), leading to limited effectiveness in treating conditions like scleroderma-associated interstitial lung disease and other fibrotic disorders.

Innovation Solution

The use of kasugamycin, a previously known antibiotic, is discovered to inhibit the mechanisms of fibrosis uniquely among aminoglycoside antibiotics, targeting Chit1 and subsequently affecting TGFβ1 signaling, thereby reducing fibrosis in fibrotic diseases by administering it to subjects with elevated Chit1 activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapeutic approaches are used for fibrotic diseases, then treatment is provided, but the approaches are inadequate in directly addressing the mechanisms of fibrosis involving Chit1 and TGFβ1

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address fibrosis mechanisms

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from conventional fibrosis treatments to kasugamycin, an aminoglycoside antibiotic with unique ability to inhibit Chit1 enzyme activity. This parameter change enables direct targeting of the fibrosis mechanism involving Chit1 and TGFβ1 signaling, thereby improving treatment effectiveness and mechanistic adaptability simultaneously

Inventive Principle:

Principle #35Parameter changes

2Reliability

If kasugamycin is administered to inhibit Chit1 activity, then fibrosis and collagen deposition are reduced, but this represents a novel use of a previously known antibiotic

Engineering Contradiction:

Improveantifibrotic effectVSAvoidnovelty of therapeutic approach

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies multi-functionality by demonstrating that kasugamycin, originally known as an antibiotic, also possesses antifibrotic properties through Chit1 inhibition. This allows a single compound to serve multiple therapeutic functions: its traditional antimicrobial role and its newly discovered role in treating fibrotic diseases by blocking the Chit1-TGFβ1 pathway

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Kasugamycin effectively reduces fibrosis and collagen deposition in fibrotic diseases by inhibiting Chit1 activity, demonstrating significant antifibrotic effects in various models of pulmonary fibrosis, including bleomycin-induced and TGFβ1-stimulated inflammation, thereby offering a novel therapeutic strategy for fibrotic conditions.

Implementation Method 1

kasugamycin, a previously known antibiotic, displays unexpected activity in inhibiting the mechanisms of fibrosis... kasugamycin effectively reduces fibrosis and collagen deposition in fibrotic diseases by inhibiting Chit1 activity

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentEP3668511B1Kasugamycin for use in treating fibrosis

Publication Date: 2023.11.29 BROWN UNIVERSITY

Figure 1
Figure 2
Figure 3A~3B

AI summary

Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.